1219 studies found for:    TAG-72
Show Display Options
Rank Status Study
1 Terminated Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
Conditions: Colorectal Cancer;   Metastases
Interventions: Drug: Unconjugated IDEC-159;   Drug: 111In-IDEC-159;   Drug: 90Y-IDEC-159
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week Open Label Dose Extension;   Drug: 72-Week Open Label Dose Extension
3 Terminated
Has Results
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
Condition: Diabetes
Intervention: Drug: VI-0521
4 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
5 Completed
Has Results
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: double blind placebo;   Drug: double blind PR OROS methylphenidate;   Drug: open label PR OROS methylphenidate
6 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
7 Completed
Has Results
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
Condition: Schizophrenia
Interventions: Drug: Intramuscular ziprasidone mesylate;   Drug: Intramuscular haloperidol
8 Recruiting Long-Term Safety Of PF-00547659 In Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: PF-00547659
9 Recruiting Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Condition: Chronic Hepatitis B Infection
Interventions: Drug: Tenofovir DF;   Drug: Placebo to match TDF
10 Completed
Has Results
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
Condition: Post-Operative Pain
Interventions: Drug: Sufentanil NanoTab PCA System/15 mcg;   Drug: morphine IV PCA
11 Terminated
Has Results
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
Condition: Arthroplasty
Interventions: Drug: Tapentadol IR (CG5503);   Drug: Placebo;   Drug: Oxycodone HCL IR
12 Completed An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
Condition: Gastric Ulcer
Intervention: Drug: Esomeprazole Sodium
13 Recruiting Closed-loop Insulin Delivery in the General Ward
Condition: Diabetes Mellitus
Interventions: Device: Fully Automated Closed-Loop Insulin Delivery;   Device: Conventional insulin therapy
14 Completed Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.
Conditions: Pharmacokinetics of Isavuconazole;   Healthy Volunteers;   Renal Impaired
Intervention: Drug: isavuconazole
15 Recruiting Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
Conditions: Meningoccocal Disease,;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV vaccine (1 dose at study month zero);   Biological: rMenB + OMV vaccine (2 doses 1 month apart)
16 Completed
Has Results
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine;   Biological: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
17 Completed
Has Results
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine vaccines;   Biological: 1b - rMenB+OMV NZ and routine vaccines;   Biological: 2a - Routine and rMenB+OMV NZ vaccines;   Biological: 2b - rMenB+OMV NZ and routine vaccines;   Biological: 3a - rMenB+OMV NZ and routine vaccines;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine vaccines;   Biological: 4b - rMenB+OMV NZ and routine vaccines
18 Completed Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB+OMV NZ with routine vaccinations;   Biological: rMenB+OMV NZ;   Biological: two doses of rMenB+OMV NZ
19 Completed
Has Results
Multicenter, Safety Study Of Maraviroc
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infection
Intervention: Drug: Maraviroc
20 Completed
Has Results
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
Condition: Psoriasis
Interventions: Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy;   Drug: etanercept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years